论文部分内容阅读
目的:研究长期用丙酸倍氯米松(商品名:伯克纳,BDP)鼻喷雾剂治疗成人常年性变应性鼻炎(AR)对患者骨密度的影响。方法:对36例20~45岁常年性AR患者给予BDP鼻喷雾剂治疗,200μg/d≤剂量≤400μg/d,分级阶梯治疗,定期复查。根据治疗及随诊时间将36例患者分为3组,A组,治疗及随诊时间1~<3年;B组,治疗及随诊时间3~<5年;C组,治疗及随诊时间≥5年。分别于治疗前、后测患者的骨密度和血清钙、磷、碱性磷酸酶值,并进行配对资料t检验。结果:经随访观察鼻用BDP鼻喷雾剂治疗的3组成人常年性AR患者的骨密度和血清钙、磷、碱性磷酸酶均值与治疗前比较均差异无统计学意义(均P>0.05),显示鼻用BDP鼻喷雾剂剂量≤400μg/d治疗常年性AR,5年内是安全的。结论:长期鼻用BDP鼻喷雾剂200μg/d≤剂量≤400μg/d,对AR患者的骨密度及骨代谢无明显影响。
OBJECTIVE: To study the long-term effects of nasal spray with beclometasone dipropionate (Berkner, BDP) on bone mineral density in adult patients with perennial allergic rhinitis (AR). Methods: Thirty-six patients with 20-45 year-old perennial AR were treated with BDP nasal spray, 200μg / d ≤ dose ≤400μg / d, stratified ladder treatment and regular review. According to the treatment and follow-up time 36 patients were divided into 3 groups, group A, treatment and follow-up time of 1 to 3 years; group B, treatment and follow-up time of 3 to 5 years; C group, treatment and follow-up Time ≥ 5 years. The bone mineral density, serum calcium, phosphorus, and alkaline phosphatase were measured before and after treatment, and paired t test was performed. Results: The follow-up observation of nasal BDP nasal spray treatment of 3 groups of adult patients with perennial AR bone mineral density and serum calcium, phosphorus, alkaline phosphatase mean and before treatment were no significant difference (all P> 0.05) , Shows nasal BDP nasal spray dose ≤ 400μg / d treatment of perennial AR, 5 years is safe. Conclusion: Long-term nasal use of BDP nasal spray 200μg / d ≤ dose ≤ 400μg / d, no significant effect on bone mineral density and bone mineral density in patients with AR.